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Abstract
Background: Better insights into the molecular changes involved in virus-associated and -independent head
and neck cancer may advance our knowledge of HNC carcinogenesis and identify critical disease biomarkers.
Here we aimed to characterize the expression profiles in a matched set of well-characterized HPV-dependent
and HPV-independent tonsillar tumors and equivalent immortalized keratinocyte clones to define potential
and clinically relevant biomarkers of HNC of different etiology.
Methods: Fresh frozen tonsillar cancer tissues were analyzed together with non-malignant tonsillar tissues and
compared with cervical tumors and normal cervical tissues. Furthermore, relative miRNAs abundance levels of
primary and immortalized human keratinocyte clones were evaluated. The global quantitation of miRNA gene
abundance was performed using a TaqMan Low Density Array system. The confirmation of differentially expressed
miRNAs was performed on a set of formalin-fixed paraffin-embedded tumor samples enriched for the tumor cell
fraction by macrodissection.
Results: We defined 46 upregulated and 31 downregulated miRNAs characteristic for the HPV-positive tonsillar
tumors and 42 upregulated miRNAs and 42 downregulated miRNAs characteristic for HPV-independent tumors.
In comparison with the expression profiles in cervical tumors, we defined miR-141-3p, miR-15b-5p, miR-200a-3p,
miR-302c-3p, and miR-9-5p as specific for HPV induced malignancies. MiR-335-5p, miR-579-3p, and miR-126-5p were
shared by the expression profiles of HPV-positive tonsillar tumors and of the HPV immortalized keratinocyte clones,
whereas miR-328-3p, miR-34c-3p, and miR-885-5p were shared by the miRNA profiles of HPV-negative tonsillar
tumors and the HPV-negative keratinocytes.
Conclusions: We identified the miRNAs characteristic for HPV-induced tumors and tonsillar tumors of different
etiology, and the results were compared with those of the model system. Our report presents the basis for further
investigations leading to the identification of clinically relevant diagnostic and/or therapeutic biomarkers for tumors
of viral and non-viral etiology.
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Background
Head and neck cancer (HNC) mostly involves a group of
squamous cell carcinomas (HNSCC) which arise from the
epithelial cells of the mucosal lining in the head and neck
region. HNSCC belong among the six most common
cancers worldwide [1]. The most important risk factors
are smoking and alcohol consumption; however, HPV
infection is also recognized as another primary cause of
HNC. The proportion of HPV-caused HNC varies around
the world; in the USA about 40–80 % of oropharyngeal
cancers are associated with the presence and expression of
high-risk HPV (HR-HPV), whereas in Europe, this
percentage ranges from 90 % in Sweden to less than 20 %
in countries with high consumption of tobacco [2]. In the
Czech Republic, 68 % of the oropharyngeal tumors are
HR-HPV positive [3, 4]. Recently, an increasing incidence
of oropharyngeal cancers associated with HPV has been
reported in several countries [5–7]. The most prevalent
mucosal HR-HPV in HNC is HPV16 occurring in up to
90 % of HPV-positive HNC [8, 9].
Although patients with HR-HPV associated HNC often
present with more advanced disease, they have a remark-
ably better prognosis and overall survival [9, 10]. The
prognostic advantage of HNC tumors etiologically linked
to HPV could potentially lead to modified treatment regi-
mens. Besides, oropharyngeal tumors are usually not
detected in the early stages of the disease, most likely due
to the location of the lesions in the tonsillar crypts, and
the marker of early cancer formation might allow earlier
treatment and improved prognosis. Meanwhile, patients
start to be treated in the late stages of disease and their
prognosis is relatively poor. Unlike cervical cancer which
is nearly always associated with HR-HPV infection, virally
and non-virally induced HNC represent a unique model
to study cancer in the same localization that is caused by
distinct molecular mechanisms.
MicroRNAs (miRNAs) are a class of short single-
stranded non-coding RNAs. MiRNAs play an important
role in post-transcriptional regulation of gene expression
by inducing target mRNA degradation or by repressing
the translation via binding to the 3´-untranslational
region of their target mRNAs [11]. The regulation of
miRNA expression has been demonstrated to play a key
role in the development, cell growth, and differentiation
processes in a variety of eukaryotic organisms. The
expression of miRNAs is deregulated in human cancer
and their abundance profiles are often specific for
tumors of different origin where they can serve as onco-
genes or tumor suppressors. It has been shown that both
normal and cancer tissues have specific miRNA expres-
sion signatures and show differential expression across
tumor types [12]. In previous studies, it has also been
demonstrated that miRNAs are promising prognostic
and diagnostic biomarkers of human cancers [13–16].
Several studies focused on miRNA profiling in HNC
have been published in recent years. Distinct miRNA pro-
files were shown in head and neck cancer cell lines [17] as
well as in tumor tissues compared with normal tissues
[18–20]. However, to date only a few studies analyzing the
miRNA profile in HNC with regard to HPV presence have
been published. HPV-positive and HPV-negative HNSCC
cell lines were studied by Wald et al. [21]. Lajer et al. pro-
filed HPV-positive and HPV-negative oral, pharyngeal,
and oropharyngeal (OSCC, PSCC, OPSCC) and cervical
squamous cell carcinomas [22, 23] and identified the
“HPV core” miRNAs.
The aim of our study was to characterize the expression
profiles of miRNAs in well-characterized tonsillar tumors
and define miRNAs characteristic for HPV-dependent and
HPV-independent tonsillar tumors. Cervical tumors were
also evaluated as a positive control of HPV-associated tu-
mors, allowing us to identify miRNAs specific for HPV-
induced tumors. Furthermore, we compared the results of
miRNA expression profiles with the model system of
isogenic primary human keratinocyte clones immortalized
by HPV or human telomerase gene. We identified a group
of miRNAs specific for HPV-induced tumors and a group
of miRNAs specific for tonsillar carcinomas. The expres-
sion of the most differentially expressed miRNAs was con-
firmed on a large set of macrodissected tonsillar tumors by
quantitative real-time PCR (RT qPCR). Finally, we have
identified several miRNAs as potential prognostic markers
but their significance has to be determined in a larger sam-
ple set. Our results serve as a starting point for the identifi-
cation of useful and clinically relevant biomarkers of HNC
tumors of HPV-related and HPV-independent etiologies.
Methods
Clinical samples
All tonsillar tumor samples were obtained in the scope of
the ongoing study from patients treated at the Depart-
ment of Otolaryngology and Head and Neck Surgery, 1st
Faculty of Medicine, Charles University and Motol
University Hospital, Prague in the period from 2005 to
2007. The study set, i.e. 23 fresh frozen (FF) tumor sam-
ples and 64 formalin-fixed paraffin-embedded (FFPE)
tumor samples, was selected based on the virological and
immunohistochemical characteristics of the FFPE tissue
samples in our ongoing studies (p16, p53, HPV DNA, and
HPV E6 mRNA) [24] and the availability of fresh frozen
material. Normal tonsillar tissue samples (N = 5) were col-
lected from patients who underwent tonsillectomy for
non-malignant conditions. These patients were gender
and age matched to the study patients with tonsillar tu-
mors. Cervical samples, i.e. normal cervical tissues (N = 2)
and cervical tumors (N = 5), were collected from patients
treated at the Department of Obstetrics and Gynecology,
2nd Faculty of Medicine, Charles University and Motol
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University Hospital, Prague in 2012. All patients enrolled
in the study signed the informed consent form. The study
received official institutional and ethical approval from the
Motol University Hospital and Institute of Hematology
and Blood Transfusion.
For patients from whom FF tonsillar tumor samples
were obtained, data on demographics and clinical patho-
logical characteristics were completed for each patient
and collected by a questionnaire. All data are summa-
rized in Additional file 1: Table S1. All patients were
prospectively followed up.
The sampling and tissue handling for tonsillar tumor
samples in the ongoing study has been described before
[25]. Sections of fresh frozen tumor tissues were cut on
a cryostat, and the number of tumor cells was deter-
mined by a pathologist. The samples of non-malignant
tonsils were taken during the surgery and were snap
frozen in liquid nitrogen immediately after removal and
stored at −80 °C. Samples of normal cervical tissue and
cervical tumors were taken during the surgery, stored
and transported in RNAlater (Life Technologies, USA)
transport medium, and processed within 1 week. FFPE
samples were macrodissected. The area with the tumor
was labelled by an expert pathologist on a hematoxylin
stained slide and transported to the laboratory. The tis-
sue from the labelled area was scraped off and used for
immediate RNA extraction.
A set of nine isogenic primary human foreskin kera-
tinocyte clones and the w12 cell line (derived from cer-
vical carcinoma containing extrachromosomal HPV16)
were kindly provided by the collaborating laboratories at
the University of Iowa, USA. The preparation of the
clones has been previously described [26, 27]. Five of the
foreskin keratinocyte clones were immortalized by
HPV16, two were immortalized by the telomerase gene,
and the rest were primary keratinocyte cells. The cells
were stored at -80 °C and used directly for the isolation
of nucleic acids. The characteristics of analyzed clones
and cell lines are summarized in Table 1.
Processing of samples
DNA from all FF tonsillar tissues and cervical tissues
was isolated using the QIAamp DNA Mini kit (Qiagen,
Germany) and total RNA was extracted by the miRVana
kit (Life Technologies, USA) according to the manufac-
turer's protocol. For better yield, only RNA was isolated
from the cell lines. Both DNA and RNA of FFPE sam-
ples were simultaneously extracted from four 10-μm sec-
tions enriched for the tumor cells by macrodissection
using the Ambion RecoverAll™ total nucleic acid isola-
tion kit for FFPE according to the manufacturer's proto-
col (Applied Biosystems, USA).
The detection and typing of HPV DNA was performed
by a modified PCR method with broad spectrum primers
BSGP5+/6 + bio specific for the L1 region and reverse
line blot hybridization as previously described [28]. RNA
concentration and quality were measured by Experion
chip electrophoresis (Bio-Rad, USA). For the analysis of
microarrays, only FF samples with a RIN (RNA integrity
number) higher than seven were used. The expression of
HPV16 E6 mRNA was assessed by RT PCR which amp-
lifies the most abundant splice variant E6*I with a length
of 86 bp as described before [29]. The status of the HPV
genome in FF clinical samples as well as in the cell lines
was evaluated by the mapping of E2 integration break-
point and APOT assay as described recently [25].
TaqMan Low Density Array (TLDA) analysis
The global quantitation of miRNA gene expression was
performed using the TaqMan® Array Human MicroRNA
A+ B Cards Set v3.0 (Life Technologies, USA) containing
a total of 384 TaqMan® MicroRNA Assays and controls
per card. Each array contains three assays of endogenous
controls (RNU48, RNU44, and RNU6B) and one assay as
a negative control.
Overall, we analyzed 35 clinical samples and 12 cell lines.
First, 1000 ng of total RNA of each sample were reverse
transcribed using the TaqMan® MicroRNA Reverse Tran-
scription Kit and Megaplex™ RT Primers specific for each
card (both Life Technologies, USA) according to the manu-
facturer's instructions. The TLDA cards were analyzed on
the Applied Biosystems 7900HT Real-Time PCR System.
Data analysis
For data processing and evaluation, we used the SDS 2.4
and the ExpressionSuite v1.0.1. software (Life Technologies,
USA). Ct values for miRNAs identified by automated
thresholding were exported separately for cards A and B.
From the detected Ct values, the RQ (relative quantity) was
calculated using the 2^-Ct formula. The data were further
processed by the GeneSpring GX11 software (Agilent).
Based on the per-sample measurement counts (hundreds),
we selected the 50th percentile shift to perform within-
sample normalization and applied it globally across the data
sets. For comparison of two or three groups in the censored
analyses, T-test or ANOVA, in combination with the Pavli-
dis Template Matching tool (TIGR TM4 suite) was used.
Table 1 Specification of keratinocyte clones and cell lines
Type of cells Specification Number
HPV16 immortalized human
keratinocyte clones
integrated 3
extrachromosomal 1
mixed 1
HPV16-positive original w12 cell line extrachromosomal 1
primary human keratinocytes HPV-negative 2
hTERT immortalized human
keratinocyte clones
HPV-negative 2
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The P-value (P < 0.05) and fold-change (FC> 1.33) thresh-
olds were set as exploratory-stage parameters (alpha setting
only, no corrections for multiple testing were applied) in
the comparison of differential abundance of miRNAs in dif-
ferent groups of samples. All data analysis was performed
on a subset of samples (N = 10, six HPV-positive and four
HPV-negative tonsillar tumors) with high tumor fraction
(≥60 % of tumor cells). Only the miRNAs differentially
expressed in at least 3/5 (60 %) samples with a valid
(measured) result (except for groups with two samples
where all samples had to have a measured result) were
considered for further analyses.
In order to determine new variables reflecting informa-
tion on the differentially expressed miRNAs in relation to
patient prognosis, tumor size, patient age, and grading, we
applied factor analysis allowing for the reduction of the
number of variables, taking advantage of a relatively large
set of miRNAs analyzed across ten patients with tonsillar
tumor only. The set of data was reduced and the miRNAs
not expressed in two or more of ten analyzed samples
were excluded. Altogether, 368 miRNAs, prognosis, size of
tumor, age, and grading were evaluated. Additional avail-
able characteristics, such as tumor stage, nodal status,
smoking status, and alcohol consumption status, were
identical in all or almost all subjects. This analysis was
done using IBM SPSS v23.
Technical validation of microarray data
Selected miRNAs (miR-21, miR-205, let-7b, miR-24,
miR-126, miR-378, miR-141, miR-200c, miR-146b, miR-
191, and miR-484) which were found differentially
expressed by the microarrays in tonsillar samples were
further validated by the individual RT qPCR using the
TaqMan® MicroRNA Assays (Life Technologies, USA)
on the same set of samples. First, 10 ng of total RNA
was reverse transcribed using the TaqMan® MicroRNA
Reverse Transcription Kit (Life Technologies, USA) and
predesigned primers for each individual TaqMan®
MicroRNA Assay according the manufacturer's instruc-
tions. RNU48 was used as the endogenous control. For
each sample, qPCR reaction was done in triplicate and
consisted of 2 μl cDNA, 1× TaqMan® MicroRNA Assay,
5 μl of TaqMan® Universal PCR Master Mix, no AmpEr-
ase UNG (Life Technologies, USA), and nuclease-free
water. The cycling conditions were 2 min at 50 °C and
10 min at 95 °C, followed by 40 cycles of denaturation
at 95 °C for 15 s and annealing at 60 °C for 1 min. The
pool of unaffected tonsils was used as a calibrator. The
2-ΔΔCt method was used for calculations of the fold
change. The overall agreement between the microarray
data and individual assay data was excellent with the
exception of miR-378 where the directions of regulation
were opposite.
Confirmation of microarray results
The confirmation of the differentially expressed miRNAs
was performed on a large set of 64 macrodissected FFPE
tumor samples (46 HPV-positive tumors and 18 HPV-
negative tumors). The miRNA expression was assayed by
individual RT qPCR using the TaqMan® MicroRNA Assays
(Life Technologies, USA) as described above. As a calibrator,
the pool of total RNA from unaffected tonsils were used.
RNU48 was used as the endogenous control. The 2-ΔΔCt
method was used for calculations of the fold change. The
cut-off fold change was set as for the arrays to +/− 1.33.
Results
Characterization of patients and samples
Demographic and clinical pathological parameters of
patients with tonsillar tumors are summarized in
Additional file 1: Table S1. The mean age of patients with
tonsillar squamous cell carcinomas (TSCC) was 54.8 years
and most of them were males (91.3 %). All HPV-positive
tonsillar tumors contained HPV type 16 and expressed
HPV16 E6 mRNA. The analysis of HPV genome status in
HPV-positive tonsillar samples was done as published
recently [25], with 43 % of the samples containing extra-
chromosomal HPV DNA, 14 % both extrachromosomal
and integrated HPV DNA, and 36 % integrated HPV
DNA. One sample yielded inconclusive results. All
cervical tumors were HPV16-positive, whereas the non-
malignant cervical tissues were HPV-negative. The major-
ity of cervical tumors contained integrated HPV DNA.
Global miRNA profiling in the model system
MiRNA expression profiling was done in the model
system of primary and immortalized human keratinocyte
clones. As illustrated in Fig. 1, each group of the ana-
lyzed clones exhibited a very specific miRNA expression
profile in principal component analysis (PCA).
The miRNA expression profiles of human keratinocyte
clones were evaluated as a model system for clinical sam-
ples. As an analogy to the comparison of HPV-positive
and/or HPV-negative tonsillar tumors with normal tissues,
HPV16 immortalized keratinocyte clones and/or keratino-
cyte clones immortalized by the human telomerase gene
and primary keratinocytes were used. In keratinocyte
clones immortalized by HPV16, 39 miRNAs were differ-
entially expressed whilst in keratinocyte clones immortal-
ized by human telomerase gene, 30 miRNAs were found.
MicroRNAs identified as differentially expressed with the
P-value (P < 0.05) and fold-change (FC> 1.33) in the corre-
sponding comparisons are listed in Additional files 2 and
3: Tables S2 and S3. MiRNAs miR-135b-3p, miR-146b-5p,
miR-205-5p, miR-425-3p, miR-625-3p, and miR-485-3p
which are involved in signaling and cell migration con-
nected with epithelial to mesenchymal transition, tumor
invasion, and metastasis, were detected in both the
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comparison of HPV immortalized keratinocytes with
primary keratinocytes and the comparison of telomerase
immortalized clones with primary keratinocytes.
Global miRNA profiling in tumors and controls
In human tissues, non-censored PCA showed clear
separation of the two groups of samples: normal HPV-
negative cervical samples and non-malignant tonsillar
tissue samples, suggesting the tissue specificity of the
miRNA expression profile (Additional file 4: Figure S1).
Clear group separation based on the miRNA expression
profiles was also detected for the group of tumor sam-
ples and samples of normal tissue from the same ana-
tomical location (Additional file 5: Figures S2A and B).
Figure 2 summarizes the miRNA expression of HPV-
positive tonsillar tumors, HPV-negative tonsillar tumors,
and non-malignant tonsillar tissues. We included only FF
samples with more than 60 % of tumor cells which show
much better separation in comparison to all samples. We
found that tumor sample homogeneity (rather than sample
size) is important for the robustness of miRNA expression
analysis as separation is less clear if all samples irrespective
of tumor cell content are visualized (data not shown).
The comparison of the miRNA expression profiles of
tonsillar tumors and normal tonsillar tissues revealed 46
upregulated and 31 downregulated miRNAs in HPV-
positive tumors (listed in Additional file 6: Table S4) and
42 upregulated and 42 downregulated miRNAs in HPV-
negative tumors (listed in Additional file 7: Table S5).
To illustrate and identify the miRNAs specific for
HPV-induced tumors and tonsillar tumors associated
with or independent of HPV, a Venn diagram was con-
structed (Fig. 3). Altogether, we identified five miRNAs
specific for HPV-induced malignancies, the so-called
HPV-core miRNAs, common for HPV-positive TSCC
and cervical tumors (listed in Table 2). One of these five
miRNAs was inversely expressed in tonsillar and cervical
tumors. The group of miRNAs specific for HPV-positive
tonsillar tumors encompassed 30 miRNAs, and 38 miR-
NAs were exclusively specific for HPV-negative tonsillar
tumors (all miRNAs listed in Table 3). Additionally, 35
miRNAs were common to both HPV-positive and HPV-
negative tonsillar tumors which seem to be characteristic
for the anatomical location of head and neck cancer
(listed in Additional file 8: Table S6).
Comparison of miRNA profiles in clinical samples and the
model system
The aim of our study was also the comparison of miRNA
expression in clinical samples and in the model system of
keratinocyte clones. HPV-positive tonsillar tumors and
HPV-immortalized keratinocyte clones overlapped in
three miRNAs (Table 4) specific to either group. MiR-
335-5p and miR-579-3p were upregulated in both groups,
whereas miR-126-5p was upregulated in clinical samples
and downregulated in the model system. We also identi-
fied seven additional miRNAs common to these two
groups, but they were significantly deregulated either in
HPV-negative tonsillar tumors in comparison with normal
tonsils or in keratinocyte clones immortalized by human
Fig. 1 Principal component analysis plot. Visualization of miRNA
expression in model systems. Primary human keratinocytes (pHFK);
human keratinocytes immortalized by human telomerase gene
(iHFK); HPV immortalized keratinocytes (tHFK) Fig. 2 Principal component analysis plot. Visualization of miRNA
expression of tonsillar tumors and non-malignant tissues.
HPV-positive tonsillar tumors (TT+); HPV-negative tonsillar
tumors (TT-); non-malignant tonsillar tissue (NT)
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telomerase (hTERT) in comparison with primary keratino-
cytes, so they seemed not to be directly influenced by the
presence of HPV. HPV-negative tumors and hTERT-
immortalized keratinocyte clones overlap in three miR-
NAs specific to either group and nine additional miRNAs
which were common also to other groups. We detected
miRNA-328-3p which was upregulated in both groups.
Inverse patterns of expression regulation of miR-34c-3p
and miR-885-5p were found in the model system and
clinical samples.
In the groups of HPV-positive tonsillar tumors and
HPV-immortalized keratinocyte clones, we also evalu-
ated the influence of HPV status on the changes in the
miRNA expression profile. HPV-positive tumor tissues
which contain extrachromosomal, integrated, or mixed
HPV DNA differ in the miRNAs expression profiles. A
similar situation was observed in the model system of
keratinocyte clones. However, we found no overlap in
the list of miRNAs differentially expressed in HPV-
positive tumors and in HPV-immortalized keratinocytes
with a particular form of HPV DNA, but the differen-
tially expressed miRNAs were found to target the same
genetic pathways.
Confirmation of microarray results
To confirm the results of differentially expressed miR-
NAs revealed by miRNA arrays, we selected nine specific
miRNAs and confirmed their expression in a set of 64
FFPE samples by individual TaqMan miRNA assays. The
miRNAs were selected based on the fold change and
relevance in the literature. From the group of HPV core
miRNAs, we selected miR-9, miR-141, and miR-200a
which were upregulated in both groups of HPV-
associated tumors (Additional file 9: Figure S3). From
the group of the miRNAs specific for HPV-positive ton-
sillar tumors, the upregulated miR-125b-2*, miR-21, and
miR-335 were selected (Additional file 10: Figure S4).
MiR-335 was also upregulated in the model system of
Fig. 3 Venn diagram. Visualization of the number of group-specific miRNAs. HPV-positive tonsillar tumors (TT+); normal tonsils (NT);
HPV-negative tonsillar tumors (TT-); cervical tumors (CT); normal cervix (NC)
Table 2 List of HPV core miRNAs
Probe name miRNA
family
TT+ versus NTa CT versus NCb
Fold change p-value Fold change p-value
miR-141-3p mir-8 6.175 0.000197 17.039 0.002
miR-15b-5p mir-15 3.072 0.034 10.659 0.045
miR-200a-3p mir-8 8.173 0.000269 6.481 0.005
miR-302c-3p mir-302 29.111 0.093 −1862.248 0.005
miR-9-5p mir-9 24.460 0.001 177.296 0.018
aTT+ HPV-positive tonsillar tumors, NT normal tonsils
bCT cervical tumors, NC normal cervix
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HPV-immortalized keratinocyte clones. Next, miR-221
upregulated in a group of HPV-negative tonsillar tumors
was analyzed (Additional file 11: Figure S5). Finally,
miR-20b exemplified the miRNAs upregulated in HPV-
positive tonsillar tumors and downregulated in HPV-
negative tonsillar tumors, and miR-210 exemplified
those upregulated in tonsillar tumors of either etiology
(Additional file 12: Figure S6).
Table 3 List of group-specific miRNAs derived from the Venn diagram
Exclusively TT+ specifica Exclusively TT- specifica
Probe name miRNA family FCb Probe name miRNA family FCb
hsa-miR-125b-2-3p mir-10 21.689 hsa-miR-431-5p mir-431 37.879
hsa-miR-147b mir-147 16.057 hsa-miR-517c-3p mir-515 12.679
hsa-miR-523-3p mir-515 10.983 hsa-miR-485-3p mir-485 7.305
hsa-miR-542-3p mir-542 9.273 hsa-miR-623 mir-623 6.535
hsa-miR-10a-5p mir-10 4.513 hsa-miR-34c-5p mir-34 4.851
hsa-miR-202-3p mir-202 3.694 hsa-miR-221-3p mir-221 4.505
hsa-miR-34a-3p mir-34 2.854 hsa-miR-517a-3p mir-515 4.327
hsa-miR-34a-5p mir-34 2.574 hsa-miR-193b-3p mir-193 2.966
hsa-miR-21-5p mir-21 2.494 hsa-miR-193a-5p mir-193 2.620
hsa-miR-335-5p mir-335 2.378 hsa-miR-223-3p mir-223 2.518
hsa-miR-18b-5p mir-17 2.338 hsa-miR-323a-3p mir-154 2.391
hsa-miR-130b-3p mir-130 2.180 hsa-miR-1260a mir-1260a 2.202
hsa-miR-197-3p mir-197 2.077 hsa-miR-106b-3p mir-17 2.072
hsa-miR-579-3p mir-548 1.945 hsa-miR-151a-3p mir-28 1.735
hsa-miR-132-3p mir-132 1.699 hsa-let-7d-5p let-7 −1.389
hsa-miR-214-5p mir-214 −2.571 hsa-miR-30b-5p mir-30 −1.461
hsa-miR-30e-3p mir-30 −2.934 hsa-miR-487a-3p mir-154 −1.474
hsa-miR-425-3p mir-425 −3.147 hsa-let-7e-5p let-7 −1.554
hsa-miR-500a-3p mir-500 −3.333 hsa-let-7b-5p let-7 −1.582
hsa-miR-126-5p mir-95 −4.049 hsa-miR-564 mir-564 −1.590
hsa-miR-145-3p mir-145 −4.805 hsa-miR-629-3p mir-629 −1.616
hsa-miR-1247-5p mir-1247 −5.233 hsa-miR-125b-5p mir-10 −1.920
hsa-miR-505-5p mir-505 −5.344 hsa-miR-100-5p mir-10 −2.106
hsa-miR-30a-3p mir-30 −5.981 hsa-miR-30d-5p mir-30 −2.145
hsa-miR-136-3p mir-136 −6.714 hsa-miR-26b-3p mir-26 −2.369
hsa-miR-486-5p mir-486 −7.824 hsa-miR-29a-3p mir-29 −2.397
hsa-miR-1179 mir-1179 −8.498 hsa-miR-130b-5p mir-130 −2.647
hsa-miR-1 mir-1 −10.729 hsa-miR-642a-5p mir-642 −2.768
hsa-miR-575 mir-575 −11.791 hsa-miR-328-3p mir-328 −2.806
hsa-miR-133a-3p mir-133 −24.685 hsa-miR-744-3p mir-744 −2.998
hsa-miR-520d-3p mir-515 −3.135
hsa-miR-99a-5p mir-10 −3.404
hsa-miR-29c-3p mir-29 −3.474
hsa-miR-139-3p mir-139 −3.666
hsa-miR-885-5p mir-885 −3.725
hsa-miR-138-5p mir-138 −12.185
hsa-miR-142-3p mir-142 −15.980
hsa-miR-150-5p mir-150 −17.261
aTT+ HPV-positive tonsillar tumors, TT- HPV-negative tonsillar tumors
bFC fold change
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The expression of all above-mentioned miRNAs was
confirmed in a set of FFPE macrodissected tumors. The
values of fold changes based on individual assays were
then compared with the values obtained with miRNA
arrays (Fig. 4). The cut-off fold change for significantly
deregulated miRNAs was set as for arrays to +/− 1.33.
All individually analyzed miRNAs showed concordance
of the expression with the results obtained with arrays,
with the exception of miR-21. Although the trend in
expression was maintained, the upregulated expression
of miR-21 was confirmed only in 50 % of samples, and
the median of absolute fold change in all samples was
equal to 1.27. The deregulated expression of the other
miRNAs was confirmed (miR-9 in 100 %, miR-141 in
59 %, miR-200a in 87 %, miR-125b-2* in 89 %, miR-335
in 54 %, miR-221 in 67 %, miR-20b in 93 % of HPV-
positive tumors and in 87 % of HPV-negative tumors,
and miR-210 in 100 % of tumors of both etiologies).
Prognostic miRNAs
The expression of 738 miRNAs was evaluated in ten
tonsillar tumor samples. In order to evaluate if the ana-
lyzed miRNAs correspond with the clinical characteris-
tics or patient prognosis, we performed the factor
analysis. At first we compute the principal components
and for them we made varimax rotation to obtain best
view to data. The loading of obtained factor is displayed
in Additional file 13: Figure S7, the components of the
particular rotated factor are listed in Additional file 14:
Table S7. For the analysis we used IBM SPSS v.23. One
hundred percent of the variance can be explained by
eight groups of factors and prognosis was the most
strongly associated with miRNAs from group 5, which
in total explains about 10.3 % of the variability. Twelve
miRNAs in group 5 (miR-196b, miR-485-3p, miR-589,
miR-324-3p, miR-342-3p, miR-92a1#, miR-155, miR-
146b, miR-142-3p, miR-1260, miR-143, and miR-142-5p)
have strong loading (absolute value ≥ 0.8).
Discussion
While the incidence of head and neck tumors of non-
viral etiology is declining, the head and neck tumors
associated with human papillomavirus infection are
steadily increasing [5, 30]. The presence of HPV remains
the strongest prognostic factor in HNC compared to
HPV-negative tumors [9, 31]. Thus, the task of advan-
cing knowledge on molecular pathogenesis of the disease
and identifying diagnostic and prognostic biomarkers
remains of key importance. Our aim was to characterize
the expression profiles of miRNAs in well-characterized
tonsillar tumors and define the miRNAs characteristic of
HPV-associated or HPV-negative tonsillar tumors. Next,
we wanted to compare the results from clinical samples
with those obtained from the model system of isogenic
primary human keratinocyte clones immortalized by
HPV or human telomerase gene.
MicroRNA profiling in HNC has been reported in
several studies, but the published data lack comparabil-
ity, likely due to the anatomical heterogeneity of the
studied tumors and differences in the methodological
approaches. Tran et al. profiled miRNAs in a set of head
and neck cancer cell lines [17], similarly to Chang et al.
who have compared results from cell lines with the
miRNA profiles from a small group of four tumor
samples [32]. Afterwards, studies performed on tumor
tissues from various locations have been published [18-
20, 33]. However, none of these studies addressed a
comparison between HPV-associated and HPV-
independent tumors, although other studies analyzed the
miRNA profiles in cell lines or clinical samples with
regard to the HPV status. Wald et al. have studied the
miRNA profiles in head and neck squamous cell carcin-
oma (HNSCC) cell lines [21], identifying a number of
deregulated miRNAs and describing the influence of
HPV oncogene E6 on the miRNA profiles. Lajer et al.
analyzed a set of 51 oral and pharyngeal tumors in com-
parison to the normal tissues, reporting deregulation of
21 miRNAs in nine HPV-positive samples [22]. This
study became extended to include a set of tonsillar and
cervical tumors, and to identify miRNAs with roles in
HPV-associated pathogenesis [23]. However, both these
studies lacked confirmation of the transcriptionally
active HPV infection. Hui et al. have identified several
miRNAs associated with HPV status in a set of oropha-
ryngeal carcinomas and suggested candidate miRNAs
correlating with the patients’ clinical outcome [34].
Recently, Miller et al. have identified a miRNA subset in
oropharyngeal carcinomas, validating the analysis in the
clinical data from The Cancer Genome Atlas [35].
Table 4 List of significantly deregulated (P < 0.05) miRNAs in
clinical samples vs. the model system
Probe name miRNA family tHFK vs. pHFKa TT+ vs. NTb
Fold change Fold change
hsa-miR-335-5p mir-335 8.361 2.378
hsa-miR-579-3p mir-548 7.921 1.945
hsa-miR-126-5p mir-95 2.580 −4.049
Probe name miRNA family iHFK vs. pHFKa TT- vs. NTb
Fold change Fold change
hsa-miR-328-3p mir-328 −22.020 −2.806
hsa-miR-34c-5p mir-34 −16.419 4.851
hsa-miR-885-5p mir-885 48.377 −3.725
atHFK HPV-immortalized human foreskin keratinocyte clones, pHFK primary
human foreskin keratinocyte clones, iHFK hTERT-immortalized human
keratinocyte clones
bTT+ HPV-positive tonsillar tumors, TT- HPV-negative tonsillar tumors
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Fig. 4 Comparison of fold change for particular miRNAs between arrays and qPCR. HPV-positive tonsillar tumors (HPV+ TT), HPV-negative tonsillar
tumors (HPV- TT). The fold change (FC) threshold was set to 1.33
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Here we analyzed the miRNA expression profiles of
well-characterized tonsillar tumors and in a set of kera-
tinocyte clones, providing a first-of-its-kind comparison
of the miRNA profiles in clinical samples with regard to
the presence of HPV, with a model system of keratino-
cyte clones. Keratinocyte clones immortalized by HPV16
and primary keratinocytes were used as the model sys-
tem for the HPV-positive tumors and/or normal tissues,
whilst the keratinocyte clones immortalized by human
telomerase gene mimicked HPV-independent tumors.
When comparing the two types of immortalized kera-
tinocyte clones against primary cells, in order to identify
the miRNAs characteristic for immortalized cells regard-
less of the mode of immortalization, miR-135b-3p and
miR-146b-5p were downregulated while miR-205-5p was
upregulated in both types of immortalized keratinocyte
clones. This is in agreement with other miRNA profiling
studies of different carcinomas and cell lines including
HNC, and these miRNAs have been shown to participate
in the signaling pathways and cell migration pathways
connected with epithelial to mesenchymal cell transition
(EMT), tumor invasion, and metastasis [36–38]. Next,
we identified the miRNAs specific either for the HPV-
immortalized keratinocyte clones or the hTERT-
immortalized clones. The most upregulated miRNA in
HPV-immortalized clones was miR-454-5p, reported previ-
ously as upregulated in human colorectal cancer cells [39].
Another highly upregulated miRNA was the tumor
suppressor-like miR-335, linked to longer survival in cer-
vical cancer patients [40, 41]. The most downregulated
miRNAs in HPV-immortalized keratinocyte clones were
miR-33a-5p and miR-133b. Wong et al. have demonstrated
the tumor suppressor role of miR-133b in oral cell lines
through the dysregulation of pyruvate kinase type M2
(PKM2) [42]. MiRNA-146a, here observed to be downregu-
lated in HPV-immortalized keratinocytes, is also regulated
by HPV oncoproteins, indirectly through the activation of
c-Myc oncogene via viral E7 protein (reviewed by [43]).
The most upregulated miRNAs in hTERT-immortalized
keratinocyte clones were less-studied miR-627-5p and
miR-885-5p, although miR-885-5p has been reported to
act as the post-transcriptional regulator of CASP3 expres-
sion which has anti-apoptotic and carcinogenic effects
[44]. MiR-199a-3p and miR-146b-5p were the most down-
regulated miRNAs in hTERT-immortalized clones. Several
studies focused on the tumor type-dependent function of
miR-199-3p in tumors and cell lines have found that its
downregulation enhances proliferation, invasiveness, and
adhesion [45] and it is a predictor of worse prognosis in
patients with osteosarcoma [46].
In this study, we showed that each group of tumors
has a specific miRNA profile. The most upregulated
miRNAs in HPV-positive tonsillar tumors were miR-
125b-2-3p and miR-147b while the most downregulated
were miR-133a-3p and miR-575. MiR-125b-1 and miR-
125b-2 originated from independent precursors located
in different chromosomal loci, but their targets are iden-
tical. In contrast to our data, Nakanishi et al. have re-
vealed the loss of miR-125b-1 to contribute to head and
neck cancer development [47] and Henson et al. have
reported decreased expression of miR-125b in oral
cancer cells [48]. In the context of HPV infection,
Nuovo et al. have observed that miR-125b has a role in
productive HPV infection and that its upregulation leads
to the reduction in viral DNA [49]. However, other miR-
NAs found to be upregulated in HPV-positive tumors in
our study were also identified to play a role in cancer
(e.g. miR-34a, miR-21, miR-10a, or some mir-30 family
members). MiR-133a, tumor suppressor miRNA down-
regulated in several types of cancer including HNSCC,
was also downregulated in our set of HPV-positive
tumors [50–52]. MiR-133a has been shown to be
involved in inhibition of cell proliferation, migration and
invasion in HNSCC cell lines [53, 54].
In HPV-negative tumors, miR-431-5p and miR-517c-3p
were the most upregulated and miR-150-5p and miR-142-
3p the most downregulated miRNAs. Dysregulation of
miR-150 has been demonstrated in a number of solid tu-
mors (reviewed in [55]). Additionally, miR-485, miR-34c,
miR-221, or miR-193a and miRNAs from the mir-10 or let-
7 families identified as deregulated in HPV-negative tumors
in our study participate in the regulation of proliferation,
apoptosis, and invasion, and have been proposed as a prog-
nostic indicators in patients with solid cancers [56–60].
As mentioned above, only three studies analyzed the
miRNA profiles in head and neck tumors with regard to
the HPV status. Lajer et al. addressed the miRNA
profiles in HNC and compared the miRNA profiles of
HPV-positive and HPV-negative HNSCC and cervical
carcinomas, identifying a group of HPV-associated core
miRNAs [22, 23]. Negligible overlap with their results
was found in our study most likely due to the heterogen-
eity in the analyzed samples in Lajer´s study. Lajer et al.
compared cervical tumors with a pool of HPV-positive
tonsillar and pharyngeal carcinomas while in our study
only well-characterized tonsillar tumors were evaluated.
Our results do agree with theirs only in the identifica-
tion of miR-21, the most commonly elevated miRNA in
cancers. In agreement with the study of Hui et al. [34],
we identified miR-9 as associated with the HPV status
since it was upregulated in both tonsillar and cervical
tumors. Recent studies have shown miR-9 to be involved
in the pathways regulating metastasis [61]. Liu et al. [62]
have shown that HPV-induced activation of miR-9 leads
to the increase of cell motility through downregulation
of genes involved in the pathways of cell migration.
MiR-9 has also been considered as HPV-associated by
Miller et al. using the bioinformatics analysis [35].
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Despite the small overlap in the identified HPV core
miRNAs with Lajer´s study the other HPV core miRNAs
identified in our study have been previously mentioned as
players in cancer development. Myklebust et al. have
reported miR-15b to be strongly associated with the ex-
pression of several E2F-related genes [63] and its expres-
sion to be reduced after HPV16 E7 knockdown. MiR-141
has been found to be overexpressed in HPV-positive cer-
vical carcinomas [64]. Members of the mir-8 family, which
includes also miR-200a, are the major regulators of the
EMT pathway, primarily targeting transcriptional factors
ZEB1 and ZEB2 [65]. MiR-302c-3p inversely expressed in
tonsillar and cervical tumors in our study has been shown
before as miRNA inhibiting the tumor growth [66].
The aim of our study was to compare the miRNA ex-
pression profiles in clinical samples and in the model
system of keratinocyte clones. The overlap between par-
ticular clinical samples and the model system was very
small. The miRNA profiles of HPV-positive tonsillar tu-
mors and HPV-immortalized clones overlap in three
miRNAs while one was inversely expressed in clinical
samples and in keratinocyte clones. HPV-negative tu-
mors and hTERT-immortalized clones overlap also in
three miRNAs. Two were expressed inversely in the two
groups, miR-328-3p was downregulated in both groups,
and decreased expression of this miRNA has also been
reported in other carcinomas [67, 68].
Because we have done the detailed analysis of the HPV
genome status in our HPV-positive tonsillar tissues and
keratinocyte clones, we were able to evaluate the differences
in the expression miRNA profiles in relation to the status
of the viral genome. Tumor tissues which contain either
extrachromosomal, integrated, or mixed form of HPV gen-
ome differ in their miRNA expression profiles, as was docu-
mented in the model system as well. Even though there is
no overlap in the lists of miRNAs in tumors and HPV-
immortalized keratinocytes regarding the genome status,
the differentially expressed miRNAs were found to target
the same pathways; pathways in cancer, p53 signaling, cell
cycle regulation, and PI3K-Akt signaling pathways.
We confirmed the expression of nine specific miRNAs
by individual TaqMan assays in a set of 64 FFPE samples.
For some of these miRNAs the deregulated expression
was not confirmed in all samples; miR-21 was deregulated
in 50 % of FFPE samples, miR-335 in 54 %, miR-141 in
59 % and miR-221 in 67 %. This is most likely due to the
difference in the number of tumor cells in the samples.
For arrays FF samples with >60 % of tumor cells were used
while for RT qPCR macrodissected FFPE samples contain-
ing only the tumor cells were analyzed. The expression
profiles of less deregulated miRNAs can be easily influ-
enced by the presence of non-malignant cells. The deregu-
lation of all others miRNAs was confirmed in more than
80 % of FFPE samples.
Patients with tonsillar tumors included in our study
were followed up for a long time, and we wanted to
explore the relationship between the miRNA expression
and patient prognosis. Since the number of variables
was high and the number of samples with the completed
analysis of 738 miRNAs was low, factor analysis was per-
formed. Twelve miRNAs in this group (miR-196b, miR-
485-3p, miR-589, miR-324-3p, miR-342-3p, miR-92a-1#,
miR-155, miR-146b, miR-142-3p, miR-1260, miR-143,
and miR-142-5p) seem to be influential on patient prog-
nosis. The majority of these miRNAs have been reported
as prognostic markers in different types of cancers, while
miR-324-3p, miR-155, miR-142-3p, and miR-143 have
been identified as prognostic indicators in head and neck
tumors of different locations [69–73]. The expression
levels of these miRNAs merit further validation in a
larger set of tonsillar tumors.
Conclusions
In conclusion, we characterized the miRNA expression
profiles of HPV-associated and HPV-independent
tumors and compared the results with those obtained in
the primary and immortalized human keratinocyte
clones. Our data show that the miRNA profiles differ
between tissues of different anatomical origin. Tumor
tissues exhibited site-specific miRNA expression profiles,
but the heterogeneity of the miRNA profiles in tonsillar
tumors was much larger than in cervical tumors. We
established that tumor sample homogeneity (rather than
sample size) is important for the robustness of the
miRNA expression analysis. We identified miRNAs spe-
cific for either tonsillar carcinomas or HPV-associated
tumors and the results were compared with the data
from the human keratinocyte clone model. The expres-
sion levels of the selected miRNAs were confirmed in a
larger set of tonsillar tumor samples. Finally, we evalu-
ated the differentially expressed miRNAs in relation to
patient prognosis. Our results warrant further confirm-
ation in a larger set of samples to allow future in-depth
investigations of the role played by particular miRNAs in
head and neck tumorigenesis.
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